Search | Clinical Trials Finder

Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin; Other · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 8 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2022
U.S. locations: 97
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more

Conditions: Multiple Sclerosis
Interventions: 4.5 mg Naltrexone, Naltrexone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 86 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bioavailability
Interventions: Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Restless Legs Syndrome
Interventions: Levetiracetam (Keppra); Drug
Lead sponsor: Sleep Health Centers; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma
Interventions: Pazopanib, Pazopanib Hydrochloride, Sapanisertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 460
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more

Conditions: Type 2 Diabetes Mellitus
Interventions: EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release); Drug
Lead sponsor: Elcelyx Therapeutics, Inc.; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: CHF 4226 pMDI, Placebo, Moxifloxacin; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Non-small Cell Lung Cancer, Vomiting, Nausea, Emesis
Interventions: FOSAPREPITANT (Emend), Placebo; Drug
Lead sponsor: Ajeet Gajra; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more

Conditions: Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions: PIPE-791, Placebo; Drug
Lead sponsor: Contineum Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more

Conditions: Chronic Pancreatitis
Interventions: Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Subjects, Pharmacokinetics of YM178
Interventions: YM178 OCAS, Ketoconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Aphasia
Interventions: Active tDCS plus Speech-Language Therapy, Sham plus Speech-Language Therapy; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: HFNC only, HFNC + CNEP10, HFNC + CNEP20, HFNC + CNEP30; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York

Conditions: Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions: Dulaglutide 0.75Mg/0.5Ml Inj Pen; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Alisertib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Biophilic Environmental Design, Traditional Exercise Design
Interventions: Exercise Environment; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Menstruation
Interventions: tampon D, tampon M, tampon T, tampon V; Device
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Insomnia Disorder
Interventions: ACT-541468, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: h-Patch; Device
Lead sponsor: Valeritas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain
Interventions: VX-548; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Astigmatism
Interventions: Placebo Lenses, Spherical Lenses, Toric Lenses; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 39 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy Subjects
Interventions: Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD
Interventions: Racemic formoterol, Arformoterol tartrate inhalation solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more

Search by objective public record fields.

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

Effects of Transcranial Direct Current Stimulation in Post-stroke Aphasia

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

This Study Explores Whether Adding Natural Elements Like Plants and Sunlight to Indoor Gyms Makes Exercise Feel Easier, More Enjoyable, and Improves Performance. By Comparing Workouts in Nature-inspired and Plain Gym Settings, it Aims to Find Better Ways to Design Fitness Spaces in Cities.

In-use Study of Four Different Tampons

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)